SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Irofulven

            Therapeutic Area: Oncology Product Name: LP-100

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lantern Pharma

            Deal Size: $18.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement July 26, 2021

            Details:

            Irofulven is a well-studied small molecule that causes bulky single strand DNA adducts that cause DNA damage in cancer cells, which can only be repaired by the transcription coupled nucleotide excision repair (TC-NER) pathway.